0001062993-24-002841.txt : 20240212
0001062993-24-002841.hdr.sgml : 20240212
20240212174356
ACCESSION NUMBER: 0001062993-24-002841
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240208
FILED AS OF DATE: 20240212
DATE AS OF CHANGE: 20240212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CRANDELL KEITH
CENTRAL INDEX KEY: 0001219039
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39941
FILM NUMBER: 24621615
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BYBEE CLINTON
CENTRAL INDEX KEY: 0001219043
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39941
FILM NUMBER: 24621614
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GILLIS STEVEN
CENTRAL INDEX KEY: 0001229592
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39941
FILM NUMBER: 24621612
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burow Kristina
CENTRAL INDEX KEY: 0001569248
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39941
FILM NUMBER: 24621613
MAIL ADDRESS:
STREET 1: 8755 W. HIGGINS ROAD
STREET 2: SUITE 1025
CITY: CHICAGO
STATE: IL
ZIP: 60631
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sana Biotechnology, Inc.
CENTRAL INDEX KEY: 0001770121
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 188 EAST BLAINE STREET, SUITE 400
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: (206) 701-7914
MAIL ADDRESS:
STREET 1: 188 EAST BLAINE STREET, SUITE 400
CITY: SEATTLE
STATE: WA
ZIP: 98102
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-02-08
0001770121
Sana Biotechnology, Inc.
SANA
0001219039
CRANDELL KEITH
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO
IL
60631
0
0
1
0
0001219043
BYBEE CLINTON
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO
IL
60631
0
0
1
0
0001569248
Burow Kristina
8755 W. HIGGINS ROAD,SUITE 1025
CHICAGO
IL
60631
0
0
1
0
0001229592
GILLIS STEVEN
8755 W. HIGGINS ROAD, SUITE 1025
CHICAGO
IL
60631
0
0
1
0
0
Common Stock
2024-02-08
4
P
0
363637
5.50
A
10667387
I
See Footnote
Common Stock
10301250
I
See Footnote
Common Stock
2024-02-08
4
P
0
727272
5.50
A
12446022
I
See Footnote
Common Stock
2024-02-08
4
P
0
727272
5.50
A
12446022
I
See Footnote
Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to to the extent of any pecuniary interest therein.
Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.
This Form 4 is one of two reports relating to the same transaction being filed jointly by ARCH IX, AVP IX LP, ARCH IX Overage, AVP IX Overage LP, AVP IX LLC, ARCH X, AVP X LP, ARCH X Overage, AVP X Overage LP, AVP X LLC, Keith Crandell, Clinton Bybee, Kristina Burow and Steven Gillis (collectively, the "Reporting Persons"). Robert Nelsen has direct ownership of Common Stock and is filing his own Form 4 separately.
/s/ Keith Crandell, By: Mark McDonnell, attorney in-fact
2024-02-12
/s/ Clinton Bybee, By: Mark McDonnell, attorney in-fact
2024-02-12
/s/ Kristina Burow, By: Mark McDonnell, attorney in-fact
2024-02-12
/s/ Steven Gillis, By: Mark McDonnell, attorney in-fact
2024-02-12